With all the bad news coming out of the pharmaceutical industry lately, drug-company investors have to be wondering whether they should be bailing out before more trouble hits...
NEW YORK — With all the bad news coming out of the pharmaceutical industry lately, drug-company investors have to be wondering whether they should be bailing out before more trouble hits.
Safety questions about some of the nation’s best-known drugs have set off a stock-selling epidemic that may not slow soon. While that’s stirring up concerns about all drug companies and their stocks, some analysts think the negative reaction may be overdone.
“People need to remember that the drug companies aren’t going out of business,” said Herman Saftlas, an analyst at Standard & Poor’s. “Yes, we have had some setbacks, but the vast majority of drugs are safe.”
Pharmaceutical stocks, long attractive to both individuals and institutions because of their solid earnings and growth potential, are increasingly under attack amid concerns about some of the industry’s blockbuster drugs.
Most Read Stories
- Man shot at UW no racist, friends insist, despite shooter’s claim
- We need real solutions to vehicle campers | Editorial
- Crowd comparison: Inauguration Friday and women's march Saturday
- Man struck, killed by Link light-rail train in Rainier Valley
- Will Seahawks keep Luke Willson? That's among questions facing tight end position in offseason
The worries began nearly three months ago when Merck & Co. withdrew its Vioxx drug after a study showed a group of patients taking it for 18 months had double the risk of heart attacks and strokes than those taking a placebo. With estimates putting its potential legal costs at as high as $18 billion, Merck’s stock has fallen about 30 percent since the Sept. 30 announcement.
That seemed like an isolated bit of trouble until a triple hit of industry news Dec. 17.
The biggest surprise was from Pfizer, which said a study had found an increased risk of heart attacks in patients taking high dosages of its top-selling arthritis pain reliever Celebrex. While the company plans to continue to sell Celebrex, the Food and Drug Administration says it is considering warning labels for the drug or withdrawing it from the market.
That same day, AstraZeneca said its lung-cancer drug Iressa failed to prolong survival when compared with a sugar pill, and Eli Lilly & Co. added a boldface warning to the label for its drug Strattera, indicating the ADHD medicine should be discontinued in patients suffering from jaundice or liver injury.
Since that news broke, Pfizer shares have tumbled about 7 percent and AstraZeneca stock has fallen about 10 percent. Eli Lilly, which fell as much as 4 percent on its Strattera announcement, has recouped most of those losses.
Those declines have pushed the S&P pharmaceutical index down about 10 percent this year, compared with nearly a 9 percent gain in the S&P 500 stock index over the same period.
Some of the selling may just be a result of investors’ sensitivity to adverse news out of the drug sector. Still, just a hint of risk is enough to spur some drug-sector analysts to tell their clients to get out of pharmaceutical stocks.
Also worrisome to some is the potential that long-term earnings growth will slow amid increasing competition and pricing pressures as the new Medicare drug plan goes into effect in 2006.
Hibernia Southcoast Capital analyst Bennett Weintraub advised his clients this week to direct their investments away from pharmaceutical stocks and into biotechnology shares.
In a note to clients, he said drug companies increasingly are relying on revenues from drugs already on the market, demonstrating their diminishing ability to develop new drugs through their internal research-and-development efforts. Biotech companies, in contrast, have more drugs in the pipeline.
Yet not all analysts back an immediate exit from all drug stocks. Some note the drug sector has long been among the most profitable in the U.S. economy and there are solid opportunities as baby boomers age and require more medicine.
“The drug business overall is not at risk. Specific companies may be at risk,” S&P’s Saftlas said.